MOLCURE Inc. today announced the successful completion of its first project under a joint research agreement with Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. The agreement aims to use MOLCURE’s AI-driven drug discovery platform technology to develop innovative antibody drugs for central nervous system targets (https://prtimes.jp/main/html/rd/p/000000009.000083912.html). Following completion of the first project, MOLCURE and Teijin Pharma have signed a contract for a continuation project.

  In this joint research, MOLCURE utilized its proprietary AI-driven drug discovery platform, built around a large-scale language model specifically developed for antibodies, to tackle optimization challenges with Teijin Pharma. Having generated promising new lead antibodies, the two companies have entered into a continuation project agreement and are exploring ways to further expand their collaboration.

  “We are pleased that Teijin Pharma values MOLCURE’s AI-based lead optimization technology and has chosen to move ahead with a continuation project,” said Satoshi Tamaki, CEO and CSO of MOLCURE. “We are excited to have the opportunity to use our AI-driven drug discovery platform to significantly advance Teijin Pharma’s drug discovery program. I hope that our partnership will lead to new therapies that improve the prognosis and quality of life for patients worldwide.”

About MOLCURE

MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that other technologies cannot reach. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka. Learn more at https://molcure.com.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people in 20 countries. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated sales of JPY 1,005.5 billion  and total assets of JPY 1,061.3 billion  in the fiscal year ending March 31, 2025.
Visit www.teijin.com